Infectious Disease
Mucormycosis
6
Pipeline Programs↗
5
Active Trials↗
5
Companies Involved↗
Mucormycosis is an early-stage landscape with 6 programs across 5 companies. The most active players are Novartis, Gilead, Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). 2 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 23
Phase 3
No programs
Analysis
Trial Status
7
clinical trials
Recruiting3 · 43%
Completed2 · 29%
Active, not recruiting1 · 14%
Not yet recruiting1 · 14%
Clinical Trials
Trial Activity
7 trials
Amphotericin Versus Posaconazole for Pulmonary Mucormycosis
Recruiting·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 2·NCT05468372·50 enrolled
Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety Study
Active, not recruiting·—·N/A·NCT07191756·150 enrolled
Antifungal Drugs in Pulmonary Mucormycosis
Not yet recruiting·—·Phase 4·NCT06756191·312 enrolled
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
Completed·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 2·NCT00419770·20 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)